Recombinant Mouse OX40 Ligand / TNFSF4 Protein, His Tag, 50 µg

Background
Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

Source
Recombinant Mouse OX40 Ligand, His Tag (TN4-M5241) is expressed from human 293 cells (HEK293). It contains AA Gln 49 - Leu 198 (Accession # P43488-1).
Predicted N-terminus: His

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 18.3 kDa. The protein migrates as 20 kDa and 22-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target
Croft, Esfandiari, Chong et al
Am J Clin Dermatol (2024)
(2)  "The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
Mestiri, El-Ella, Fernandes et al
Biomed Pharmacother (2024) 171, 116095
(3) "New molecular targets in the treatment of rheumatoid arthritis
Wallace, Cooney, Fox
Curr Opin Rheumatol (2024)
Showing 1-3 of 959 papers.